Now that the third quarter has concluded, it is time to brace for another earnings-reporting season. Are these nine Dow Jones industrials poised to have explosive upside if there are any positive...
Friday's top analyst upgrades and downgrades included AES, Ambarella, Beyond Meat, Bloom Energy, Facebook, Home Depot, SunPower, Tesla and Valero Energy.
Thursday's top analyst upgrades and downgrades included Boston Scientific, CVS Health, FMC, Lennar, NovoCure, Penn National Gaming, Ruth's Hospitality, Stitch Fix and Veeco Instruments.
Pharmacy and health insurer CVS handily beat expected earnings and revenue estimates for the second quarter.
This is a preview of a few of the most anticipated quarterly reports due this week, including CVS Health, Uber and Walt Disney.
Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing,...
As the number of confirmed COVID-19 cases have spiked over the last few weeks, hitting new records in major cities and states across the country, so have the number of face-covering mandates. 24/7...
See why UBS feels these 10 stocks in a variety of sectors with solid upside potential could do very well with a Trump victory in November.
Thursday's top analyst upgrades and downgrades included Activision Blizzard, Akamai Technologies, Avis Budget, BlackRock, Consolidated Edison, DocuSign, Livongo Helath, Nu Skin Enterprises, Rio Tinto...
Wednesday's top analyst upgrades and downgrades included AGCO, Anthem, AT&T, Caterpillar, Comcast, Cogent Communications, CVS Health, DraftKings, FedEx, Papa John's, Square and UnitedHealth.
Rite Aid stock jumped by more than 25% after reporting first-quarter earnings Thursday morning. We've seen this action before.
Friday's top analyst upgrades and downgrades included Adobe, Analog Devices, Caterpillar, ConocoPhillips, General Motors, Southwest Airlines, Take-Two Interactive Software and Tesla.
Ambarella shares retreated even though it released better-than-expected quarterly results late Tuesday.
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
As companies around the world struggle to mitigate the damage caused by the coronavirus pandemic, executive leadership is being put to the test. CEOs are facing intense scrutiny for how and when they...